The Motley Fool··Thomas NielAbbVie's Unbroken Dividend Streak: 10+ Years of Increases Despite Patent Cliff
AbbVie maintains 10+ years of consecutive dividend increases despite Humira patent loss, buoyed by blockbuster drugs Skyrizi and Rinvoq projected to reach $50B by 2030.
ABBVABTearnings growthdividend growth